TruScreen Group Limited has launched a NZ$1.22 million Share Purchase Plan offering discounted shares to eligible investors, aiming to fuel growth in key international markets and public health initiatives.
TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.
TruScreen Group Ltd reports a dip in FY25 sales but forecasts a robust rebound in FY26 driven by resumed programs and expansion in key emerging markets. Strategic partnerships and AI-enabled technology underpin its growth ambitions.